Krebs Biochemicals & Industries Limited (BOM:524518)

Market Cap	1.50B -5.9%
Revenue (ttm)	252.34M -29.7%
Net Income	-140.94M
EPS	-6.53
Shares Out	21.56M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,595
Open	59.00
Previous Close	60.30
Day's Range	59.00 - 71.75
52-Week Range	38.52 - 76.72
Beta	0.90
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About BOM:524518

Krebs Biochemicals & Industries Limited engages in the manufacture of active pharmaceutical ingredients in India. It offers androstenedione for steroid intermediate indications, as well as lovastatin and simvastatin for anti-cholesterol applications. The company also develops amlodipine and telmisartan for anti-hypertension; cetirizine for antihistamine; orlistat for anti-obesity; serratiopeptidase for anti-inflammatory; and phenylephrine for cold and cough. In addition, it provides contract manufacturing services for large pharmaceutical and m...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1991
• Employees: 142
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524518

Financial Performance

In fiscal year 2026, BOM:524518's revenue was 237.32 million, a decrease of -45.21% compared to the previous year's 433.12 million. Losses were -169.33 million, -37.14% less than in 2025.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 4, 2026

Data Sources Report a data error